北京若生智能科技有限公司
Drug Database
AZ

azithromycin (Azimac)

✓ Approved

Beijing Holley-Cotec Pharma · 小分子 · 小分子

什么是 azithromycin？

azithromycin 是一种小分子，由Beijing Holley-Cotec Pharma研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Azimac
公司Beijing Holley-Cotec Pharma
药物类别小分子
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Beijing Holley-Cotec Pharma

治疗适应症

azithromycin 针对 8 个适应症，涉及 3 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsLower respiratory tract infection✓ Approved
Infections and infestationsOtitis media✓ Approved
Infections and infestationsSinusitis✓ Approved
Infections and infestationsTonsillitis✓ Approved
Infections and infestationsUrinary tract infection✓ Approved

注册免费账户还可查看另外 3 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedBMC infectious diseases2026-10-26

Azithromycin versus ceftriaxone for uncomplicated typhoid fever in children: a systematic review and meta-analysis of randomized controlled trials.

Manzoor Muhammad Umair MU, Anwar Aqsa A, Owais Muhammad M, Umar Syed S et al.

Typhoid fever caused by Salmonella enterica serovar Typhi remains a major cause of febrile illness among children in low- and middle-income countries, particularly in South and Southeast Asia. The increasing emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains has substantially limited available treatment options and highlighted the need for effective oral therapies. Azithromycin and ceftriaxone are commonly used for uncomplicated typhoid fever in children; however, evidence comparing their efficacy and safety remains limited. To compare the efficacy and safety of azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children through a systematic review and meta-analysis of randomized controlled trials. A comprehensive literature search was conducted in PubMed, the Cochrane Library, ClinicalTrials.gov, Google Scholar, and WHO ICTRP from inception to April 2026 in accordance with PRISMA 2020 guidelines. Randomized controlled trials comparing azithromycin with ceftriaxone in children under 18 years of age with uncomplicated typhoid fever were included. The primary outcome was the clinical cure rate. Secondary outcomes included fever clearance time, microbiological cure, relapse, and adverse events. Data extraction and risk of bias assessment using the Cochrane Risk of Bias 2 tool were performed independently by two reviewers. Meta-analysis was conducted using a random-effects model, and heterogeneity was assessed using the I² statistic. Six randomized controlled trials involving 492 children (azithromycin = 244; ceftriaxone = 248) were included. All studies were open-label trials conducted in Egypt, India, Pakistan, and Bangladesh. Overall risk of bias was judged to be of some concern, mainly due to the open-label study design. Meta-analysis showed no significant difference between azithromycin and ceftriaxone in clinical cure rate (RR = 0.98, 95% CI 0.93-1.03; P = 0.43) or fever clearance time. Similarly, microbiological cure and adverse event profiles were similar across groups but could not be formally pooled due to heterogeneous reporting. However, azithromycin was associated with fewer relapses than ceftriaxone, though this finding should be interpreted with caution given the low certainty of the evidence. The certainty of evidence was very low for fever clearance and low for the relapse rate. Heterogeneity varied across outcomes, with the highest for fever clearance time. Azithromycin appears to have comparable efficacy and safety to ceftriaxone for the treatment of uncomplicated typhoid fever in children, with a trend toward fewer relapses that warrants cautious interpretation. Its oral administration may provide a practical alternative to parenteral ceftriaxone in endemic settings. Further large-scale randomized trials with standardized outcome reporting are needed to strengthen the current evidence base. Not applicable. PROSPERO Protocol Number: CRD420261383999. LINK: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261383999 .

PMID 42928111
阅读全文 →
PubMedRevista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia2026-10-25

Azithromycin as macrolide of choice in patients with preterm premature rupture of membranes in expectant management.

Bosi Fernanda Castilhos FC, Müller Gabriel Cardozo GC, Vettorazzi Janete J, Vettori Daniela Vanessa DV et al.

This study seeks to demonstrate that the use of antibiotics, with azithromycin as macrolide of choice, in expectant management reduces the birth rate in the first 48 hours after PPROM, increasing the latency period between PPROM and birth. Observational, retrospective cohort study in pregnant women with PPROM treated conservatively at the Hospital de Clínicas de Porto Alegre, from January 2012 to December 2019. For the group that used antibiotics, the scheme was Azithromycin and Ampicillin for 48 hours, followed by Amoxicillin for 5 days, completing 7 days of treatment. 145 participants, of which 107 did not use antibiotics (Group 1) and 38 used antibiotics (Group 2). The 48-hour birth rate was significantly lower in the antibiotics group (33.6% in Group 1 vs. 16% in Group 2, p=0.04). The birth rate on patients presenting outcomes before 15 days presented a significant reduction (HR 0.6 [95% CI 0.39-0.92]), as well median time to birth as seen in Kaplan-Meier estimator by log-rank test. The use of this antibiotic's regimen, with azithromycin as macrolide of choice, reduces delivery within 48 hours, with potential clinical benefits due to the increase in the pharmacological window for corticosteroid action, among others, and increased median time to birth in first 15 days between PPROM and birth.

PMID 42924378
阅读全文 →
PubMedIJID regions2026-10-25

Epidemiology and antimicrobial susceptibility of Vibrio cholerae in recurrent cholera outbreaks in Ethiopia: a multicenter study.

Ayenew Zeleke Z, Kalayu Alem Abrha AA, Ibrahim Rajiha Abubeker RA, Demlie Yeshambel Worku YW et al.

The recurrence of cholera continues to be a public health concern in Ethiopia. The emergence of antimicrobial-resistant Vibrio cholerae strains has complicated case management. Thus, this study aimed to assess the epidemiologic distribution and antimicrobial susceptibility profile of V. cholerae in Ethiopia. A cross-sectional study was conducted among patients in cholera treatment centers and health care facilities in Ethiopia from September 2023 to September 2025. Diarrheic stool and suspected water samples were collected and transported to the Ethiopian Public Health Institute to isolate and confirm V. cholerae using standard microbiology techniques. Antimicrobial susceptibility testing was performed by the Kirby-Bauer disc diffusion and E-test methods in accordance with updated Clinical and Laboratory Standards Institute guidelines. Among 356 stool samples and 30 water samples, 66.3% and 3.3% were culture-positive for V. cholerae, respectively. All isolates were confirmed as V. cholerae O1 serotype Ogawa across all regions. The isolates were 100% susceptible to chloramphenicol and meropenem, 99.6% to tetracycline and 99.2% to ciprofloxacin but all isolates were resistant to azithromycin 98.7% to ampicillin and trimethoprim-sulfamethoxazole. Nearly all isolates were multidrug-resistant (99.6%). V. cholerae O1 Ogawa was the only serotype circulating in a long-standing cholera outbreak in Ethiopia, with a high prevalence of multi-drug resistant. A high rate of azithromycin resistance highlights the urgent need to revise national cholera treatment guidelines.

PMID 42921463
阅读全文 →
PubMedIndian journal of medical microbiology2026-10-25

Beyond the Gut: Genome-Characterised Salmonella Kentucky ST198 Urinary Tract Infection.

Roy Mahuya M, Singh Inderjit I, Kumar Dhananjay D, Sumui Bhaskar B et al.

Non-typhoidal Salmonella urinary tract infections (UTIs) are rare and may be linked to immunosuppression, chronic illnesses, or structural urinary tract abnormalities. Salmonella enterica serovar Kentucky (ST198) is a globally disseminated lineage associated with fluoroquinolone resistance and the acquisition of additional antimicrobial resistance (AMR) determinants. This is the first Indian case report of a rare UTI caused by Salmonella Kentucky ST198, resistant to both fluoroquinolones and extended-spectrum cephalosporins. This report emphasises the value of whole-genome sequencing (WGS) for serovar-level characterisation and resistance-gene discovery in uncommon Salmonella isolates, as well as the importance of off-label azithromycin use for treating UTI for a favourable outcome.

PMID 42925990
阅读全文 →
PubMedbioRxiv : the preprint server for biology2026-10-25

Protein-level mapping reveals novel Immune State Types (ISTs) associated with Chlamydia trachomatis infection, inflammatory remodeling, and scarring in trachoma-hyperendemic Amhara Ethiopia.

Shi Xiaoyi Charlotte XC, Olagoke Olusola O, Titiheruw Brianna Renatte BR, Chung Seongwon S et al.

Trachoma remains the leading infectious cause of blindness. Over 100M people are at risk, and 1.9M already live with visual impairment or blindness. Ethiopia bears the greatest burden of disease with ∼61M or 59% of the known affected global population. Although Chlamydia trachomatis ( Ct ) infection initiates disease, infection alone fails to explain why inflammation resolves in some but progresses to irreversible scarring and vision loss in others. Previous studies have largely examined gene expression or limited protein panels, leaving the conjunctival immune protein environment poorly characterized. We hypothesized that distinct conjunctival immune states capture these pathogenic processes and could reveal biomarkers for selecting treatment and surveillance strategies. We conducted a cross-sectional study of 667 participants residing in the hyperendemic Amhara region of Ethiopia at least one year after the most recent azithromycin mass drug administration to treat Ct . The upper tarsal conjunctivae was graded for TF and TI, trachomatous inflammation-follicular or intense, respectively; I-TS/TT, inflammation with scarring with or without trichiasis, defined as one or more eyelashes touching the globe of the eye; and TS and TT, scarring with or without trichiasis but no inflammation. T0 represented no trachoma. The protein concentrations of 41 immune mediators were quantified using Meso Scale Discovery electrochemiluminescence immunoassays. Associations with infection and grade were evaluated using covariate-adjusted models with false discovery rate correction. Bernoulli mixture modeling (BMM) revealed four distinct Immune State Types (ISTs). Both approaches supported a shared biological framework characterized by selective immune activation in Ct infection, broad inflammation in TF/TI, and chemokine remodeling versus immune quiescence in the scarred conjunctiva. Ct infection was associated with a focused IFN-γ-centered response. IST1 captured this immune response where 51.9% of the participants had Ct ; we therefore termed IST1 "Quiescent Infection." In contrast, TF/TI was associated with higher concentrations of proinflammatory, Th1/Th17, chemokine, regulatory, and remodeling pathways mediators. This profile fit well within IST2, termed "Broad Inflammation", where 72.4% of the participants had TF/TI. TS/TT retained considerable chemokine activity, whereas I-TS/TT showed a narrower, IL-17A-dominant inflammatory profile. BMM separated scarring into two states characterized by distinct profiles: IST3, "Conjunctival Remodeling," with significantly stronger chemokine and T-cell maintenance signals; and IST4, "Quiescent Scarring," with the majority of chemokines being significantly downregulated. This suggests that scarred conjunctiva can retain substantial immune activity or shift toward a more attenuated state. This study establishes the first IST framework for trachoma, revealing biologically distinct immune states with different potential clinical implications. IST1 indicates the need for antibiotic treatment, whereas IST2 suggests that novel immunotherapeutics might be effective in thwarting disease progression. The upregulated chemokines in IST3 may indicate risk of progression to TT necessitating prospective studies and potential novel antifibrotic interventions. Together, our findings provide a strong biological foundation for stratifying patients by immune state and matching them to preventive and therapeutic care. Prospective validation and streamlined biomarker panels will support the translation of this framework into field settings to help avert disease progression and blindness.

PMID 42926396
阅读全文 →
PubMedInternational journal of STD & AIDS2026-10-24

Asymptomatic extragenital Neisseria gonorrhoeae infection among transgender women in Argentina: Prevalence, antimicrobial susceptibility, and molecular characterization.

Spadaccini Luciana L, Vacchino Martin M, Gianecini Ariel A, Mernies Gissella G et al.

BackgroundAsymptomatic extragenital Neisseria gonorrhoeae (NG) infection contributes to ongoing transmission and may facilitate the emergence of antimicrobial resistance. This study aimed to determine NG prevalence, antimicrobial susceptibility patterns, and sequence types among transgender women (TGW).MethodsReal-time PCR (qPCR) and culture for NG were performed on pharyngeal and rectal swabs and first-void urine (FVU) samples from TGW attending Fundación Huésped in Buenos Aires, Argentina (August 2021-March 2022). Quantification cycle (Cq) values from qPCR-positive samples were used as a proxy for bacterial load. Culture-positive isolates underwent antimicrobial susceptibility testing and NG multi-antigen sequence typing (NG-MAST). Participants were also tested for other sexually transmitted infections (STI) and sociodemographic and behavioral data were collected by questionnaire.ResultsWe included 117 TGW: median age 32 (IQR 29-39), 55% had not completed high school, 54% were currently engaged in sex work, 55% had ≥ 5 sexual partners in the last month, and 68% reported recreational substance use in the previous year. At baseline, 46% were living with HIV, 20% had active syphilis, and 6% extragenital chlamydia. Global NG prevalence (determined by positive qPCR) was 9% (10/117) with 9 rectal infections (8%; 9/116), one pharyngeal infection (1%; 1/117), and none detected in FVU. Only three of nine PCR-positive rectal samples yielded a positive culture. All isolates were susceptible to ceftriaxone and azithromycin and showed intermediate susceptibility or resistance to tetracycline. Sequence types (ST) were ST21119, ST8202, and ST21122. No associations were found between asymptomatic extragenital NG infection and sociodemographic/behavioral factors. Seventy percent of positive PCR samples had a Cq ≥ 28, suggesting lower bacterial loads.ConclusionAsymptomatic extragenital NG infection prevalence among TGW in Buenos Aires was 9%, with no infections detected in FVU, underscoring the importance of extragenital screening. Limited culture recovery highlights the potential value of complementary approaches to antimicrobial resistance surveillance.

PMID 42920356
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多azithromycin